Alexion Soliris Warning Letter Prompts Staff Changes, Pre-emptive SEC Filing
Executive Summary
Agency says Alexion did not adequately investigate multiple bacterial contaminations and does not appear to have a robust quality system; FDA found repeat GMP violations from previous inspection.